The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC

The most frequent mechanism of resistance after 1st/2nd-generation (G) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is secondary point mutation Thr790Met (T790M) in EGFR. Afatinib followed by osimertinib (Afa group) may provide better outcomes for T790M-positive non-smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamiya, Motohiro, Tamiya, Akihiro, Okamoto, Norio, Taniguchi, Yoshihiko, Nishino, Kazumi, Atagi, Shinji, Hirashima, Tomonori, Imamura, Fumio, Kumagai, Toru, Suzuki, Hidekazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099906/
https://www.ncbi.nlm.nih.gov/pubmed/33953280
http://dx.doi.org/10.1038/s41598-021-89006-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099906/
https://www.ncbi.nlm.nih.gov/pubmed/33953280
http://dx.doi.org/10.1038/s41598-021-89006-9

Ejemplares similares